Immunome, Inc.
IMNM Real Time Price USDRecent trades of IMNM by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by IMNM's directors and management
Government lobbying spending instances
-
$10,000 Jul 16, 2022 Issue: Health Issues
-
$10,000 Oct 18, 2021 Issue: Health Issues
-
$20,000 Jul 20, 2020 Issue: Health Issues
Estimated quarterly lobbying spending
IMNM Revenue by Segment or Geography
New patents grants
-
Patent Title: Immunoconjugates and methods Apr. 08, 2025
-
Patent Title: Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma Feb. 25, 2025
-
Patent Title: Immunoconjugates and methods Jan. 07, 2025
-
Patent Title: Epha2 antibodies Dec. 10, 2024
-
Patent Title: Antibody cocktail against sars-cov-2 spike protein Dec. 05, 2023
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to IMNM
Recent picks made for IMNM stock on CNBC
ETFs with the largest estimated holdings in IMNM
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IMNM stock a Buy, Sell, or Hold?
- What is the price target for $IMNM stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IMNM stock?
- Who owns the most shares of $IMNM stock?
- What funds own $IMNM stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IMNM Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.